Bamlivimab + etesevimab therapy induces SARS-COV-2 immune escape mutations and secondary clinical deterioration in Covid-19 patients with B cell malignancies

Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19

Résumé en anglais

Bamlivimab and etesevimab are IgG1 monoclonal antibodies (mAbs), that bind to SARS-Cov2 Spike receptor-binding domain. Treatment with bamlivimab 2800mg and etesevimab 2800mg has been shown to significantly reduce SARS-CoV-2 viral load at day 11 in mild to moderate COVID-19 patients (1). In the phase 3 part of the BLAZE-1 trial, the risk of Covid-related hospitalization or death was reduced by 70% in patients treated with this combination versus placebo (2).
Subsequently, a temporary use authorization for bamlivimab 700 mg and etesevimab 1400mg association was approved in France to treat patients presenting with high risk of developing severe COVID19 infection.
Therefore, we treated 34 cancer patients presenting with a mild to moderate form of SARS-Cov-2 infection and no need for oxygen therapy, within 5 days of their first symptoms, with bamlivimab 700mg plus etesevimab 1400mg. Median age was 62.5 [31 - 83] years old. Most patients presented with a solid tumor (N=24, 71%); 10 (29%) had hematological malignancies and 47.1% were receiving chemotherapy.